Caribou Biosciences vs X4 Pharmaceuticals
CRBU and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and XFOR compare
X4 Pharmaceuticals is the larger company, worth 8.4 times as much as Caribou Biosciences ($306M against $36.5M).
X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus 10.0% for Caribou Biosciences).
X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −1030% at Caribou Biosciences.
Caribou Biosciences scores higher on the StockData Score (9 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | XFOR |
|---|---|---|
| Size and price | ||
| Market cap | $36.5M | $306M |
| Share price | $0.341 | $3.09 |
| Change, 1 year | −82.9% | −15.6% |
| Change, 5 years | −98.1% | −97.7% |
| Beta (5Y) | 1.41 | 1.45 |
| Employees | 97 | 45 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 30.9× |
| P/B | 0.4× (better) | 2.2× |
| FCF yield | −262% | – |
| Fair value | $1.29 | – |
| Margin of safety | 73.7% | – |
| Growth | ||
| Revenue growth (TTM) | 10.0% | 73.7% (better) |
| Revenue growth, 5Y average | −2.0% | 16.7% (better) |
| Profitability | ||
| Gross margin | – | 68.8% |
| Operating margin | −1091% | −812% (better) |
| Net margin | −1030% | −813% (better) |
| FCF margin | −954% | – |
| Return on equity | −78.3% (better) | −80.3% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9.3× |
| Current ratio | 6.49 | 13.22 (better) |
| Altman Z-score | −7.47 | −2.11 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −66.3% | – |
| Shareholder yield | −66.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 103% |
| Held by insiders | 5.7% | 12.2% |
| Insider net buying, 12 months | −$47.5K (better) | −$451K |
| Short interest, % of float | 14.7% | 9.2% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- XFOR stock overview
- XFOR income statement
- XFOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.